| M | T | W | T | F | S | S | |
|---|---|---|---|---|---|---|---|
 | 1 | 2 | |||||
| 3 | 4 | 5 | 6 | 7 | 8 | 9 |
| 10 | 11 | 12 | 13 | 14 | 15 | 16 |
| 17 | 18 | 19 | 20 | 21 | 22 | 23 |
| 24 | 25 | 26 | 27 | 28 | 29 | 30 |
ANTISENSE THERAPEUTICS LIMITED (ANP)
Stock Code: ANP
Listing Date: 2001-12-20 00:00:00
Website: http://www.antisense.com.au/
Industry: Pharmaceuticals, Biotechnology & Life Sciences
Principal Activities:
The development of novel antisense pharmaceuticals for commercially important human conditions.
Address:
10 Wallace Avenue, Level 1
TOORAK
VIC 3142
Phone: (03) 9827 8999
Fax: (03) 9827 1166
Executives & Directors
Mr Robert Moses, Chairman
Mr Mark Diamond, CEO
Mr Chris Belyea, Non Exec. Director
Prof. Graham Mitchell, Non Exec. Director
Prof. George Werther, Non Exec. Director
Mr Phillip Hains, CFO
Ms Kate Plumridge (Joint Co. Secretary), Company Secretary
Company Podcasts
Subscribe to current and future audio events for this company by clicking on the podcast icon:
Company ASX Announcements
Company ASX announcements can be viewed on the ASX website.
Announcements from the preceding six months are shown below.
Click here to view this company's details on the ASX site
Company Events
ANP - Commencement of Phase IIa Multiple Sclerosis Trial - Mr Mark Diamond, CEO
|
|
Thu, 29 Jun 2006 02:00PM |
| Annual General Meeting | Fri, 31 Oct 2008 10:00AM |
|
| Full Year Results | Wed, 13 Aug 2008 | |
| Interim Results | Mon, 4 Feb 2008 | |
| Annual General Meeting | Wed, 21 Nov 2007 10:00AM |
|
| EGM | Wed, 28 Mar 2007 | |
| Interim Results | Tue, 30 Jan 2007 | |
| Annual General Meeting | Tue, 10 Oct 2006 11:00AM |
|
| Full Year Results | Mon, 7 Aug 2006 | |
| Interim Results | Fri, 17 Feb 2006 | |
| Annual General Meeting | Thu, 20 Oct 2005 |
ANTISENSE THERAPEUTICS LIMITED (ANP)
| ATL1101 intellectual property portfolio strengthened | Wed, 19 Nov 2008 |
| Change of Director`s Interest Notice - RM | Thu, 6 Nov 2008 |
| Change of Director`s Interest Notice - RM | Wed, 5 Nov 2008 |
| Annual General Meeting Presentation | Fri, 31 Oct 2008 |
| Results of 2008 Annual General Meeting | Fri, 31 Oct 2008 |
| ANP to Present at Rodman and Renshaw Healthcare Conference | Tue, 28 Oct 2008 |
| Appendix 3B | Mon, 27 Oct 2008 |
| Change of Director`s Interest Notice - GW, RM, MD, CB, GM | Mon, 27 Oct 2008 |
| ATL1101 Preclinical Data in Prostate Cancer-US Presentation | Fri, 17 Oct 2008 |
| ATL1101 suppresses tumours in prostate cancer animal study | Wed, 15 Oct 2008 |
| Appendix 4C - Quarterly Cashflow Report | Tue, 14 Oct 2008 |
| Notice of Annual General Meeting | Wed, 24 Sep 2008 |
| ANP and Isis Investor Conference Call Webcast | Mon, 22 Sep 2008 |
| Teva Pharmaceuticals Announcement re MS World Congress | Tue, 16 Sep 2008 |
| Investor Presentation | Wed, 10 Sep 2008 |
| ATL/TV1102 data to be presented at MS Scientific Meeting | Thu, 28 Aug 2008 |
| Results of Meeting | Tue, 26 Aug 2008 |
| Appendix 4E and Annual Financial Report | Wed, 13 Aug 2008 |
| Market Update | Tue, 5 Aug 2008 |
| Trading Halt | Mon, 4 Aug 2008 |
| Trading Halt Request | Mon, 4 Aug 2008 |
| Key journal highlights IGF-1R as high interest cancer target | Thu, 31 Jul 2008 |
| Appendix 4C - Quarterly Cashflow Report | Thu, 24 Jul 2008 |
| Market Update | Wed, 23 Jul 2008 |
| Notice of General Meeting | Tue, 22 Jul 2008 |
| Notice of Meeting Clarification | Tue, 22 Jul 2008 |
| ANP Business and Strategy Update | Mon, 21 Jul 2008 |
| Phase lla MS Trial Success - Teva to continue development | Mon, 30 Jun 2008 |
| CIR: CIR associate ANP achieves Phase IIa MS trial success | Mon, 30 Jun 2008 |
| Trading Halt | Thu, 26 Jun 2008 |
| ANP to present to Isis Shareholders in the US | Mon, 2 Jun 2008 |
| ATL1103 On Path to Clinic with Start of Toxicology Studies | Tue, 6 May 2008 |
| Change in substantial holding | Tue, 22 Apr 2008 |
| Notice under s708A(5)(e) | Fri, 18 Apr 2008 |
| ANP completes ATL1102 Phase IIa Multiple Sclerosis Trial | Thu, 17 Apr 2008 |
| Appendix 3B | Thu, 17 Apr 2008 |
| Placement | Wed, 16 Apr 2008 |
| Appendix 3B | Wed, 16 Apr 2008 |
| Appendix 4C - quarterly | Tue, 8 Apr 2008 |
| ATL1102 Phase IIa Multiple Sclerosis Trial Update | Tue, 1 Apr 2008 |
| Research Director Receives 2008 Advancing BioBusiness Award | Wed, 26 Mar 2008 |
| Final Director`s Interest Notice - FB | Mon, 17 Mar 2008 |
| Resignation of Non-Executive Director | Thu, 6 Mar 2008 |
| ANP to present at US Investor Conference | Fri, 22 Feb 2008 |
| Trading Halt | Mon, 11 Feb 2008 |
| ATL1102 Licensed to Teva Pharmaceuticals Ltd | Mon, 11 Feb 2008 |
| Market Update - MS drug Tysabri sales | Thu, 7 Feb 2008 |
| Half Year Accounts - 31 December 2007 | Mon, 4 Feb 2008 |
| ATL1102 Phase IIa Multiple Sclerosis Trial Update | Fri, 21 Dec 2007 |
| ANP Updated Company Profile | Mon, 17 Dec 2007 |
Please note: This company appears on this website as a result of its listing on the Australian Securities Exchange. Boardroom Radio does not claim any association with any company listed on this site.